VRAX (Virax Biolabs Group) Beginning Cash Position: $3.35 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRAX Virax Biolabs Group Ltd VRAX
45 GF Score
Price $2.66
GF Value $3.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Virax Biolabs Group Beginning Cash Position?

Virax Biolabs Group VRAX +1.53% 45 Beginning Cash Position is $3.35 Mil as of Mar. 2026. GuruFocus rates VRAX with a GF Score™ of 45/100 and a GF Value™ of $3.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Virax Biolabs Group's Beginning Cash Position for the quarter that ended in Mar. 2026 was $3.35 Mil.

Virax Biolabs Group's quarterly Beginning Cash Position declined from Mar. 2025 ($7.29 Mil) to Sep. 2025 ($4.23 Mil) and declined from Sep. 2025 ($4.23 Mil) to Mar. 2026 ($3.35 Mil).

Virax Biolabs Group's annual Beginning Cash Position declined from Mar. 2024 ($9.35 Mil) to Mar. 2025 ($3.59 Mil) but then increased from Mar. 2025 ($3.59 Mil) to Mar. 2026 ($4.23 Mil).

Virax Biolabs Group Beginning Cash Position Related Terms

Virax Biolabs Group Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Virax Biolabs Group's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virax Biolabs Group Beginning Cash Position Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beginning Cash Position
Get a 7-Day Free Trial 0.02 0.02 9.35 3.59 4.23

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.11 3.59 7.29 4.23 3.35
VRAX
45GF Score
Virax Biolabs Group Ltd VRAX
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virax Biolabs Group Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $3.35 Mil mean?
Virax Biolabs Group (VRAX) has a Beginning Cash Position of $3.35 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Virax Biolabs Group and its competitors.
Is Virax Biolabs Group's Beginning Cash Position too high?
Virax Biolabs Group's current Beginning Cash Position is $3.35 Mil. Overall, Virax Biolabs Group has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's Beginning Cash Position compare to ISCO and PKTX?
Virax Biolabs Group's Beginning Cash Position of $3.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Virax Biolabs Group and its competitors. Virax Biolabs Group's current Beginning Cash Position is $3.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.61, compared to a current price of $2.66 — trading 26.3% below its estimated fair value. The current Beginning Cash Position is $3.35 Mil. Virax Biolabs Group's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current Beginning Cash Position is $3.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virax Biolabs Group (VRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be undervalued. The current stock price of $2.66 is trading 26.3% below its estimated GF Value™ of $3.61. GuruFocus considers Virax Biolabs Group to be Modestly Undervalued.

Key valuation signals for VRAX:

  • Beginning Cash Position: $3.35 Mil
  • GF Value™: $3.61 vs. price of $2.66 (26.3% below fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virax Biolabs Group Business Description

Address Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
45GF Score

Get the complete analysis for VRAX

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.66
Price
$3.61
GF Value